Pivekimab
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC) . Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) [1][2].
Product Specifications
CAS Number
2234335-84-1
UNSPSC
12352203
Target
ADC Antibody; Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pivekimab.html
Purity
97.19
Solubility
10 mM in DMSO
Smiles
[Pivekimab]
Molecular Weight
(145.98 kDa)
References & Citations
[1]Patrick ZM, et, al. Methods of treatment using anti-CD123 immunoconjugates. WO2020092533.|[2]Poussard, et al. Spatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model. Blood 142 (2023) : 2791.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
